Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer, Focusing on Radiopharmaceutical Growth

Ratio Therapeutics Welcomes Marcel Reichen as Chief Strategy Officer

On November 4, 2025, Ratio Therapeutics Inc., a pioneering pharmaceutical company specializing in radiopharmaceuticals, announced the significant appointment of Marcel Reichen, Ph.D., MBA, as their new Chief Strategy Officer. This strategic move is expected to enhance Ratio's growth trajectory as the company continues to innovate in the field of precision oncology.

A New Era for Ratio Therapeutics

Dr. Reichen’s vast experience in the pharmaceutical sector, particularly in radioligand therapy, positions him uniquely to drive Ratio’s strategic initiatives forward. With more than ten years of international experience, Dr. Reichen has a proven history of success in value creation and strategic planning within the pharmaceutical arena. According to Dr. Jack Hoppin, the current Chairman and CEO of Ratio Therapeutics, Reichen’s deep knowledge and expertise in radioligand therapy will play a crucial role in guiding the company's future growth. This statement reinforces the belief that Marcel's contributions will significantly strengthen Ratio's leadership position in precision oncology.

Expertise in Radioligand Therapy

Dr. Reichen expressed his enthusiasm for joining Ratio during a transformative phase in the radiopharmaceutical industry. His career has traversed various roles in discovery, business development, and corporate strategy, giving him a comprehensive understanding of the industry. His insight into how targeted radiopharmaceuticals can be effectively designed and distributed will be invaluable as Ratio aims to redefine cancer treatment methodologies. Dr. Reichen stated, "I look forward to helping shape the company’s long-term strategic direction and accelerating the translation of our technologies into meaningful treatments for patients."

Impressive Background

Before joining Ratio Therapeutics, Dr. Reichen served as Executive Director for Search and Evaluation of Radioligand Therapy (RLT) at Novartis. In this role, he provided guidance to the Oncology Leadership Team on emerging trends within the RLT sector and facilitated numerous strategic licensing and acquisition transactions. His previous work at Advanced Accelerator Applications, a part of Novartis, included managing strategic initiatives like the PET imaging strategy and conducting RLT platform reviews. His consultancy experience at Bayer Business Consulting further developed his skills in advising executive management on RD productivity and digital transformation, enhancing his capabilities in business development and licensing integration.

Dr. Reichen holds a Ph.D. in Biochemical Engineering from University College London (UCL), a Master of Science in Mechanical Engineering from ETH Zurich, and an MBA from the University of St. Gallen (HSG) in Switzerland. This academic foundation complements his practical experience and positions him as a leading figure in the realms of scientific innovation and commercial strategy.

About Ratio Therapeutics Inc.

Ratio Therapeutics Inc. is on a mission to revolutionize cancer treatments through the development of next-generation precision radiopharmaceuticals targeting solid tumors. Currently based in Boston, the company boasts a talented team of multidisciplinary experts devoted to the discovery and development of radiopharmaceuticals. Their proprietary RD platforms, Trillium™ and Macropa™, are designed to improve drug availability and tumor delivery, thereby enhancing the efficacy of treatments.

Ratio's commitment to advancing radiopharmaceuticals is further exemplified by their collaborations with manufacturing partners such as PharmaLogic and the establishment of a state-of-the-art facility in Salt Lake City, Utah. These efforts ensure a reliable and high-quality supply chain for radiopharmaceutical production.

In line with their ambitious growth plans, Ratio Therapeutics intends to commence a Phase 1/2 clinical trial examining the safety and effectiveness of its FAP-targeted radiotherapeutic for patients with relapsed or refractory soft tissue sarcoma. Additionally, the company is advancing its other promising programs, including pre-clinical assessments of [Lu-177]-RTX2358 across various cancer indications and plans to launch its Granzyme B-targeted agent for PET imaging into clinical trials by 2026.

For further updates and information, visit www.ratiotx.com and follow them on Twitter (X) and LinkedIn.